Brain inflammation as a biomarker in epilepsy

Biomarkers in Medicine

Volumn 5, Issue 5, 2011, Pages 607-614

  Vezzani, Annamaria ^b   Friedman, Alon ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

blood brain barrier; brain imaging; cytokines; glia; leukocytes; proinflammatory molecules

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; KAINIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PADGEM PROTEIN; PILOCARPINE; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD BRAIN BARRIER; BRAIN DYSFUNCTION; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL DYSPLASIA; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENCEPHALITIS; EPILEPSY; EPILEPTOGENESIS; HIPPOCAMPAL SCLEROSIS; HUMAN; METHODOLOGY; NERVE CELL EXCITABILITY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; CYTOKINES; ENCEPHALITIS; EPILEPSY; HUMANS; LEUKOCYTES;

MUS MUSCULUS;

EID: 80054797400     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.61     Document Type: Review

References (74)

1. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl Acad. Sci. USA 90(21), 10061-10065 (1993). (Pubitemid 23328251)
2. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G. TNF-a transgenic and knockout models of CNS inflammation and degeneration. J. Neuroimmunol. 72(2), 137-141 (1997). (Pubitemid 27063586)
3. Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia 50(Suppl. 2), 10-13 (2009).
4. Bartfai T, Sanchez-Alavez M, Andell-Jonsson S, et al. Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma. Ann. NY Acad. Sci. 1113, 173-177 (2007). (Pubitemid 350015019)
5. Pitkanen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol. 1(3), 173-181 (2002). (Pubitemid 37163486)
6. Dubé CM, Ravizza T, Hamamura M, et al. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J. Neurosci. 30(22), 7484-7494 (2010).
7. Rizzi M, Perego C, Aliprandi M, et al. Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol. Dis. 14(3), 494-503 (2003). (Pubitemid 37543527)
8. Riazi K, Galic MA, Pittman QJ. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res. 89(1), 34-42 (2010).
9. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat. Rev. Neurol. 7(1), 31-40 (2011).
10. Eriksson C, Van Dam AM, Lucassen PJ, Bol JG, Winblad B, Schultzberg M. Immunohistochemical localization of interleukin-1b, interleukin-1 receptor antagonist and interleukin-1b converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 93(3), 915-930 (1999). (Pubitemid 29341639)
11. Ravizza T, Boer K, Redeker S, et al. The IL-1b system in epilepsy-associated malformations of cortical development. Neurobiol. Dis. 24(1), 128-143 (2006). (Pubitemid 44416213)
12. De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur. J. Neurosci. 12(7), 2623-2633 (2000). (Pubitemid 30497055)
13. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16(5-6), 457-499 (1998). (Pubitemid 28286181)
14. Aronica E, Boer K, Van Vliet EA, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol. Dis. 26(3), 497-511 (2007). (Pubitemid 46756320)
15. Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M. Complement activation in the human brain after traumatic head injury. J. Neurotrauma 18(12), 1295-1311 (2001). (Pubitemid 34038404)
16. Ravizza T, Balosso S, Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci. Lett. 497(3), 223-230 (2011).
17. Auvin S, Shin D, Mazarati A, Sankar R. Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA. Epilepsia 51(Suppl. 3), 34-38 (2010).
18. Ravizza T, Noé F, Zardoni D, Vaghi V, Sifringer M, Vezzani A. Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1b production. Neurobiol. Dis. 31(3), 327-333 (2008).
19. Jung KH, Chu K, Lee ST, et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 23(2), 237-246 (2006). (Pubitemid 44097031)
20. Polascheck N, Bankstahl M, Loscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp. Neurol. 224(1), 219-233 (2010).
21. Holtman L, Van Vliet EA, Van Schaik R, Queiroz CM, Aronica E, Gorter JA. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res. 84(1), 56-66 (2009).
22. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci. 29(21), 6964-6972 (2009).
23. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J. Neurosci. 31(6), 2337-2347 (2011).
24. Huang X, Zhang H, Yang J, et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis. 40(1), 193-199 (2010).
25. Jensen FE. Epilepsy as a spectrum disorder: implications from novel clinical and basic neuroscience. Epilepsia 52(Suppl. 1), 1-6 (2011).
26. Pitkanen A. Therapeutic approaches to epileptogenesis - hope on the horizon. Epilepsia 51(Suppl. 3), 2-17 (2010).
27. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimers disease. Arch. Pharm. Res. 33(10), 1539-1556 (2010).
28. Tansey MG, Goldberg MS. Neuroinflammation in Parkinsons disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37(3), 510-518 (2010).
29. Marchi N, Teng Q, Ghosh C, et al. Blood- brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res. 1353, 176-186 (2010).
30. Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis. 29(1), 142-160 (2008). (Pubitemid 350180489)
31. Iyer A, Zurolo E, Spliet WG, et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 51(9), 1736-1773 (2010).
32. Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussens encephalitis. Ann. Neurol. 51(3), 311-318 (2002). (Pubitemid 34206287)
33. Pardo CA, Vining EP, Guo L, Skolasky RL, Carson BS, Freeman JM. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia 45(5), 516-526 (2004). (Pubitemid 38581564)
34. Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16(4), 413-419 (2010).
35. Maroso M, Balosso S, Ravizza T, et al. Interleukin-1b biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 8(2), 304-315 (2011).
36. Akin D, Ravizza T, Maroso M, et al. IL-1b is induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence. Neurobiol. Dis. DOI: 10.1016/j. nbd.2011.05.015 (2011) (Epub ahead of print).
37. Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia 47(11), 1761-1774 (2006). (Pubitemid 44730046)
38. Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol. Appl. Neurobiol. 37(1), 3-23 (2011).
39. van Vliet EA, Da Costa Arajo S, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130(2), 521-534 (2007). (Pubitemid 46181105)
40. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat. Rev. Neurol. 6(7), 393-403 (2010).
41. Abbott JN. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell. Molec. Neurobiol. 20(2), 131-147 (2000).
42. Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-b signaling involvement in epileptogenesis. J. Neurosci. 29(28), 8927-8935 (2009).
43. Bell MD, Perry VH. Adhesion molecule expression on murine cerebral endothelium following the injection of a proinflammagen or during acute neuronal degeneration. J. Neurocytol. 24(9), 695-710 (1995).
44. Fabene PF, Navarro Mora G, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med. 14(12), 1377-1383 (2008).
45. Librizzi L, Regondi MC, Pastori C, Frigerio S, Frassoni C, de Curtis M. Expression of adhesion factors induced by epileptiform activity in the endothelium of the isolated guinea pig brain in vitro. Epilepsia 48, 743-751 (2007). (Pubitemid 46587609)
46. Friedman A, Kaufer D, Heinemann U. Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. Epilepsy Res. 85(2-3), 142-149 (2009).
47. Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 48(4), 732-742 (2007). (Pubitemid 46587627)
48. Kim JV, Kang SS, Dustin ML, McGavern DB. Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis. Nature 457(7226), 191-195 (2009).
49. Butler T, Ichise M, Teich AF, et al. Imaging inflammation in a patient with epilepsy due to focal cortical dysplasia. J. Neuroimaging DOI: 10.1111/j.1552-6569.2010.00572.x (2011) (Epub ahead of print).
50. Kumar A, Chugani HT, Luat A, Asano E, Sood S. Epilepsy surgery in a case of encephalitis: use of 11C-PK11195 positron emission tomography. Pediatr. Neurol. 38(6), 439-442 (2008). (Pubitemid 351671985)
51. Banati RB. Visualising microglial activation in vivo. Glia 40(2), 206-217 (2002). (Pubitemid 35337378)
52. Hirvonen J, Kreisl W, Fujita M, et al. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. American Epilepsy Society. San Antonio, TX, USA (2010) (Abstract 3.230).
53. Aronica E, Crino PB. Inflammation in epilepsy: clinical observations. Epilepsia 52(Suppl. 3), 26-32 (2011).
54. Hammen T, Hildebrandt M, Stadlbauer A, et al. Non-invasive detection of hippocampal sclerosis: correlation between metabolite alterations detected by 1H-MRS and neuropathology. NMR Biomed. 21(6), 545-552 (2008).
55. Turkdogan-So¨zu¨er D, Ozek MM, Sav A, Dincer A, Pamir MN. Serial MRI and MRS studies with unusual findings in Rasmussens encephalitis. Eur. Radiol. 10(6), 962-966 (2000). (Pubitemid 30353730)
56. Mizuno S, Takahashi Y, Kato Z, Goto H, Kondo N, Hoshi H. Magnetic resonance spectroscopy of tubers in patients with tuberous sclerosis. Acta Neurol. Scand. 102(3), 175-178 (2000). (Pubitemid 30645135)
57. Tomkins O, Shelef I, Kaizerman I, et al. Blood-brain barrier disruption in post-traumatic epilepsy. J. Neurol. Neurosurg. Psychiatry 79(7), 774-777 (2008). (Pubitemid 351914722)
58. M?odzikowskα-Albrecht J, Steinborn B, Zarowski M. Cytokines, epilepsy and epileptic drugs - is there a mutual influence? Pharmacol. Rep. 59(2), 129-138 (2007). (Pubitemid 46952404)
59. Mousa SA. Cell adhesion molecules: potential therapeutic and diagnostic implications. Mol. Biotechnol. 38(1), 33-40 (2008). (Pubitemid 351378095)
60. Merrill JE, Murphy SP. Inflammatory events at the blood brain barrier: regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species. Brain Behav. Immun. 11(4), 245-263 (1997). (Pubitemid 28108136)
61. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front. Biosci. 9, 1118-1135 (2004). (Pubitemid 39060833)
62. Rentzos M, Michalopoulou M, Nikolaou C, et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J. Neurol. Sci. 228(2), 129-135 (2005). (Pubitemid 40202957)
63. Pacifici R, Paris L, Di Carlo S, Bacosi A, Pichini S, Zuccaro P. Cytokine production in blood mononuclear cells from epileptic patients. Epilepsia 36(4), 384-387 (1995).
64. Hulkkonen J, Koskikallio E, Rainesalo S, Keranen T, Hurme M, Peltola J. The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients. Epilepsy Res. 59(2-3), 199-205 (2004). (Pubitemid 38887691)
65. Matsuo M, Sasaki K, Ichimaru T, Nakazato S, Hamasaki Y. Increased IL-1b production from dsRNA-stimulated leukocytes in febrile seizures. Pediatr. Neurol. 35(2), 102-166 (2006).
66. Bauer S, Koller M, Cepok S, et al. NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp. Neurol. 211(2), 370-377 (2008).
67. Nowak M, Bauer S, Haag A, et al. Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain Behav. Immun. 25(3), 423-428 (2011).
68. Vincent A, Irani SR, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr. Opin. Neurol. 23(2), 144-150 (2010).
69. Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-d-aspartate receptor antibodies in women with new-onset epilepsy. Arch. Neurol. 66(4), 458-464 (2009).
70. Irani SR, Bera K, Waters P, et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133(Pt 6), 1655-1667 (2010).
71. Bien CG, Urbach H, Schramm J, et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 69(12), 1236-1244 (2007). (Pubitemid 47429024)
72. Emanuele E, Boso M, Brondino N, et al. Increased serum levels of high mobility group box 1 protein in patients with autistic disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(4), 681-683 (2010).
73. Kauffman MA, Moron DG, Consalvo D, Bello R, Kochen S. Association study between interleukin 1b gene and epileptic disorders: a HuGe review and meta-analysis. Genet. Med. 10(2), 83-88 (2008).
74. Tan NC, Mulley JC, Berkovic SF. Genetic association studies in epilepsy: "the truth is out there". Epilepsia 45(11), 1429-1442 (2004). (Pubitemid 39470047)